Document Detail


Valsartan plus hydrochlorothiazide: a review of its use since its introduction.
MedLine Citation:
PMID:  21728903     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: This review focuses on the role of the fixed-dose combination (FDC) drug valsartan/hydrochlorothiazide (HCTZ) in the treatment of hypertension. Effective blood pressure control often is not achieved with monotherapy and, instead, requires combinations of drugs with different mechanisms of action to produce additive or synergistic effects.
AREAS COVERED: FDC valsartan/HCTZ enhances not only efficacy for blood pressure control but also provides beneficial effects on target organs beyond that expected from arterial pressure reduction alone. Data describe key clinical trial experiences with the FDC, with particular attention to efficacy and tolerability. Literature searches of these various topics were conducted in January 2011. There is evidence of potential benefits with this combination associated with left ventricular hypertrophy, left ventricular dysfunction and renal disease. The FDC is an effective treatment for patients with hypertension and is superior to monotherapy than either drug alone.
EXPERT OPINION: In addition to the benefits of each drug, valsartan/HCTZ's metabolic interactions reduce some of the negative effects of both compounds. With its increased simplicity, minimal side-effect profile and efficacy without a significant cost penalty, valsartan/HCTZ represents an excellent choice for antihypertensive therapy.
Authors:
Jujhar Bains; William B Smith
Related Documents :
8809913 - Influence of different types of recovery positions on perfusion indices of the forearm.
7421293 - Intrapleural cough pressure in patients after thoracotomy.
12956913 - Active anterior rhinomanometry analysis in normal adult malays.
Publication Detail:
Type:  Comparative Study; Journal Article; Review     Date:  2011-07-06
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  12     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-18     Completed Date:  2011-11-28     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1975-84     Citation Subset:  IM    
Affiliation:
Department of Cardiology , University of Tennessee Medical Center, 1924 Alcoa Highway, Knoxville, TN 37920, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / administration & dosage,  adverse effects,  economics,  therapeutic use*
Animals
Antihypertensive Agents / administration & dosage,  adverse effects,  economics,  therapeutic use*
Diuretics / administration & dosage,  adverse effects,  therapeutic use*
Drug Combinations
Drug Costs
Drug Synergism
Humans
Hydrochlorothiazide / administration & dosage,  adverse effects,  economics,  therapeutic use*
Hypertension / drug therapy*,  economics,  physiopathology
Hypertrophy, Left Ventricular / prevention & control
Renal Insufficiency / prevention & control
Tetrazoles / administration & dosage,  adverse effects,  economics,  therapeutic use*
Valine / administration & dosage,  adverse effects,  analogs & derivatives*,  economics,  therapeutic use
Ventricular Dysfunction, Left / prevention & control
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Diuretics; 0/Drug Combinations; 0/Tetrazoles; 137862-53-4/valsartan; 58-93-5/Hydrochlorothiazide; 7004-03-7/Valine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A disintegrin and metalloprotease -8 and -15 and susceptibility for ascending aortic dissection.
Next Document:  The association between brain-derived neurotrophic factor Val66Met variants and psychotic symptoms i...